Biogen Inc.: 10-K Risk Factor Changes

2025 vs 2024  ·  SEC EDGAR  ·  2026-07-05
Other years: 2026 vs 2025
✓ Deterministic extraction — no AI-generated data

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

1
New Risks
0
Removed
4
Modified
25
Unchanged
🟢 New in Current Filing The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation. 🔒
🟡 Modified We may not be able to access the capital and credit markets on favorable terms, which could increase our financing costs. 🔒
🟡 Modified Our business involves environmental and operational risks, which include the cost of compliance and the risk of contamination or injury. 🔒
🟡 Modified The increasing use of social media platforms presents new risks and challenges. 🔒
🟡 Modified We built a large-scale biologics manufacturing facility and are building a gene therapy, clinical packaging and other manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped. 🔒
5 changes in this historical filing

Historical year-over-year comparisons (2025 vs 2024 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →